Stockscreener 앱 받기
22.21
0.13%
-0.03
시간 외 거래:
22.21
전일 마감가:
$22.24
열려 있는:
$22.26
하루 거래량:
592.23K
Relative Volume:
0.73
시가총액:
$1.64B
수익:
$434.49M
순이익/손실:
$504.34M
주가수익비율:
3.6932
EPS:
6.0138
순현금흐름:
$181.97M
1주 성능:
+1.79%
1개월 성능:
-2.33%
6개월 성능:
+13.84%
1년 성능:
+18.33%
1일 변동 폭
$22.16
$22.68
1주일 범위
$21.90
$22.73
52주 변동 폭
$16.52
$25.14
Innoviva Inc Stock (INVA) Company Profile
명칭
Innoviva Inc
전화
(650) 238-9600
주소
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
22.21 | 1.64B | 434.49M | 504.34M | 181.97M | 6.0138 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 개시 | BTIG Research | Buy |
| 2025-09-30 | 개시 | Goldman | Sell |
| 2025-08-11 | 개시 | Oppenheimer | Outperform |
| 2025-07-14 | 개시 | H.C. Wainwright | Buy |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-07-20 | 개시 | Goldman | Neutral |
| 2017-11-20 | 개시 | Deutsche Bank | Hold |
모두보기
Innoviva Inc 주식(INVA)의 최신 뉴스
Innoviva to Participate in Upcoming Investor Conferences - AOL.com
How Innoviva Inc. (INVA) Affects Rotational Strategy Timing - Stock Traders Daily
Innoviva (INVA) Leaves Russell Indexes, Is The Stock Still Cheap? - simplywall.st
Innoviva Inc (NASDAQ:INVA): A Decent Value Play with Strong Fundamentals - ChartMill
Enterprise value to EBITDA forward of Innoviva, Inc. – SWB:HVE - TradingView
Price to sales forward of Innoviva, Inc. – SWB:HVE - TradingView
Innoviva Inc. (INVA) Sees Modest Uptick, Testing Resistance Near $23.43Safe Entry Stocks - dars.gov.et
INVAInnoviva Inc Latest SEC Filings - Finviz
Is Innoviva (INVA) Trading Index Membership for a Deeper Bet on Nortiva Bio’s LYNX Platform? - simplywall.st
Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now? - Insider Monkey
5 Cheap Small Cap Stocks to Buy Now - Insider Monkey
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Is Innoviva (INVA) Undervalued After Nortiva Bio Launch And XACDURO Deal? - Sahm
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 2000 Growth-Defensive Index - marketscreener.com
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 3000 Growth Benchmark - marketscreener.com
INVA Forecast — Price Target — Prediction for 2027 - TradingView
How Investors Are Reacting To Innoviva (INVA) Expanding Drug Delivery Tech And XACDURO Global Partnership - Sahm
Enterprise value to EBIT forward of Innoviva, Inc. – NASDAQ:INVA - TradingView
INNOVIVA INC (NASDAQ:INVA): A Strong Growth Stock Poised for a Technical Breakout - ChartMill
Price to earnings forward of Innoviva, Inc. – NASDAQ:INVA - TradingView
(INVA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Price to book forward of Innoviva, Inc. – NASDAQ:INVA - TradingView
Enterprise value to revenue forward of Innoviva, Inc. – GETTEX:HVE - TradingView
Innoviva, Inc. Actuals & Estimates (NASDAQ:INVA) - TradingView
Innoviva, Inc. Actuals & Estimates (DUS:HVE) - TradingView
HVE Forecast — Price Target — Prediction for 2027 - TradingView
Innoviva Inc (INVA) Institutional Confidence - TradingKey
Has Innoviva Successfully Pivoted Beyond its Royalty Roots - Kavout | AI
Price to sales forward of Innoviva, Inc. – GETTEX:HVE - TradingView
Innoviva, Inc. Actuals & Estimates (SWB:HVE) - TradingView
Innoviva, Inc. Actuals & Estimates (LS:A2AC9U) - TradingView
A2AC9U Forecast — Price Target — Prediction for 2027 - TradingView
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform - Insider Monkey
BTIG Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Innoviva Inc (INVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally - Insider Monkey
INVA Maintained by BTIG -- Price Target Steady at $42.00 - GuruFocus
H.C. Wainwright Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Innoviva Is Maintained at Buy by BTIG - Moomoo
H.C. Wainwright reiterates Innoviva stock rating on drug delivery platform By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Innoviva stock rating on drug delivery platform - Investing.com
Innoviva stock trades down to $22.49 as Western Thoracic conference focus draws attention - Traders Union
Innoviva stock trades down to $22.49 as company highlights role of ATC2026 in transplant research - Traders Union
Will XACDURO Licensing Deal With Dr. Reddy’s Reshape Innoviva’s (INVA) Infectious Disease Strategy? - simplywall.st
Innoviva Inc (INVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.60%
0.04%
자본화:
|
볼륨(24시간):